Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 6Skin Neoplasms 1Recurrence 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

pembrolizumab 7Cyclophosphamide 6Paclitaxel 4Flow Cytometry 4Therapeutics 3Psychiatric Rehabilitation 3Polymerase Chain Reaction 3Cisplatin 3sargramostim 2liposomal amphotericin B 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Ondansetron 2Methylprednisolone 2Itraconazole 2Immunoenzyme Techniques 2Gemcitabine 2Filgrastim 2Etoposide 2Dexamethasone 2Caspofungin 2Carboplatin 2Calcium Dobesilate 2Bortezomib 2Aprepitant 2Analgesia 2Amplified Fragment Length Polymorphism Analysis 2tislelizumab 1temsirolimus 1tanespimycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × Propranolol × Dermatologic × Clear all
NCT02013492 2022-12-06

Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery

Ohio State University Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
1 enrolled
BreastDermatologicGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Hepatocellular, Melanoma, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡